Quick answer
What is the chemical structure of ipamorelin and how is it made? Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular formula C38H49N9O5 (about 711.9 g/mol). Three features set it apart from an ordinary peptide: an aminoisobutyric acid (Aib) residue at the N-terminus, two D-configured aromatic residues (D-2-naphthylalanine and D-phenylalanine), and an amidated C-terminus. It is made by solid-phase peptide synthesis, usually on an amide-forming resin, cleaved with acid, purified by reversed-phase HPLC and confirmed by mass. The medicinal-chemistry route that led to it started from earlier growth-hormone-releasing peptides. Supplied for laboratory research use only.
Ipamorelin looks small on paper, five residues, but each position carries a design decision. This article reads the structure residue by residue, explains why those choices matter for stability and receptor recognition, and walks through how a molecule like this is assembled and checked in the laboratory. It is a chemistry companion to the broader ipamorelin research overview and what is ipamorelin. The facts about the supplied material come from the V8 ipamorelin 10 mg product page.
The sequence, position by position
The product page gives the sequence as Aib-His-D-2-Nal-D-Phe-Lys-NH2, supplied as a 10 mg lyophilized powder with purity stated as ≥98% by HPLC. Reading from the N-terminus, each residue contributes something specific.
| Position | Residue | Nature | What it contributes |
|---|---|---|---|
| 1 | Aib (aminoisobutyric acid) | Non-proteinogenic, achiral, two methyl groups on the alpha carbon | Restricts backbone rotation and shields the first peptide bond |
| 2 | His | Proteinogenic, imidazole side chain | Aromatic, ionizable, a common receptor-contact residue in this peptide family |
| 3 | D-2-Nal (D-2-naphthylalanine) | Non-proteinogenic D-aromatic | Large hydrophobic surface; protease-resistant configuration |
| 4 | D-Phe | D-amino acid | Hydrophobic aromatic; protease-resistant configuration |
| 5 | Lys-NH2 | Proteinogenic, basic, C-terminal amide | Positive charge; removes the free carboxylate |
The mass follows from the formula. Summing standard atomic masses for C38H49N9O5 gives about 711.9 g/mol, so a protonated ion in a positive-mode mass spectrum is expected near m/z 712.4. That number is the identity check a laboratory would look for. See HPLC vs mass spectrometry for what each method can and cannot prove.
Lineage: from enkephalin analogs to a pentapeptide
The structure is the end of a chain of design work. In 1981 Momany and colleagues described growth-hormone-releasing peptides designed from weakly active enkephalin analogs, using conformational energy calculations and repeated cycles of design, synthesis and testing; their most active compound at the time was Tyr-D-Trp-Ala-Trp-D-Phe-NH2 (Momany 1981). Bowers and colleagues then characterized the hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6), which released growth hormone in vitro and in vivo without a concomitant release of LH, FSH, TSH or prolactin in the studies reported (Bowers 1984).
Ipamorelin was described in 1998. Raun and colleagues report that it was identified within a series of compounds lacking the central dipeptide Ala-Trp of GHRP-1, as the outcome of a chemistry program (Raun 1998). The abstract describes a pentapeptide with GH-releasing potency and efficacy in vitro and in vivo comparable to GHRP-6, acting through a GHRP-like receptor. The removal of the Ala-Trp unit from the sequence is the structural headline: a shorter molecule that keeps the pharmacophore that matters for receptor recognition. For the receptor side of the story see ipamorelin vs GHRP-2.
Why Aib, D-amino acids and an amide matter
Aib is the odd residue. Because its alpha carbon carries two methyl groups, it has far less conformational freedom than a standard amino acid, and structural studies of peptides containing Aib show a strong preference for helical conformations (Karle and Balaram 1990). In a five-residue peptide a full helix is not expected, but the restricted rotation still limits the shapes the N-terminus can adopt. The same bulk makes the adjacent peptide bond hard for many peptidases to approach, which is the usual rationale for placing Aib at a vulnerable end.
The two D-residues work together. Peptidases are built to cleave L-amino-acid chains, so D-aromatic residues in the middle of the sequence give resistance to enzymatic cleavage and also change how the side chains present to a receptor. The C-terminal amide removes a negative charge and, in this family, matches the amidated terminus of the earlier GHRPs. The practical consequence in the lab is that ipamorelin has no methionine, cysteine or tryptophan to oxidize and no asparagine or aspartate to rearrange, so its chemical weak points differ from those of larger peptides; storing research peptides covers the general stability rules.
How a peptide like ipamorelin is synthesized
Solid-phase peptide synthesis, introduced by Merrifield in 1963, builds the chain one residue at a time on an insoluble resin (Merrifield 1963). For a C-terminal amide, the chain is anchored through a linker that releases an amide on acid cleavage. Synthesis runs from the C-terminal Lys toward the N-terminal Aib. Each cycle removes a temporary protecting group from the amine, couples the next protected residue with an activating reagent, and washes away excess reagents.
| Stage | What happens | Typical concern for this sequence |
|---|---|---|
| Resin loading | First residue, Lys with side-chain protection, anchored | Loading level affects yield |
| Chain assembly | Repeated deprotect, couple and wash cycles | Coupling onto and of hindered residues such as Aib and 2-Nal |
| Cleavage | Acid releases the peptide and removes side-chain groups | Scavengers protect the aromatic side chains |
| Purification | Reversed-phase HPLC separates product from by-products | Close-eluting diastereomers and deletion sequences |
| Isolation | Pooled fractions are freeze-dried | Counterion and residual water remain in the mass |
| Analysis | HPLC purity and mass confirmation | Purity by HPLC is not net peptide content |
The hindered residues make coupling the critical step. A failed coupling leaves a deletion sequence, a peptide missing one residue, and a partly racemized histidine or D-residue produces a diastereomer that elutes close to the product. Both are reasons why purity is read from a chromatogram together with a mass check rather than from the label. Freeze-drying converts the pooled fractions into the solid supplied in the vial; the process is described in what is lyophilization.
The lineage side by side
| Compound | Sequence | Length | Reported in |
|---|---|---|---|
| Momany lead analog | Tyr-D-Trp-Ala-Trp-D-Phe-NH2 | 5 residues | Momany 1981 |
| GHRP-6 | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 | 6 residues | Bowers 1984 |
| Ipamorelin | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | 5 residues | Raun 1998 |
Set next to each other, the three show a consistent theme: alternating D-aromatic residues, a basic residue near the C-terminus and an amidated end. What changes from GHRP-6 to ipamorelin is the loss of the Ala-Trp unit, the swap of the N-terminal histidine for Aib followed by histidine, and the replacement of D-Trp by the larger D-2-Nal. Because the original paper describes the compound as emerging from a systematic chemistry program rather than a single rational redesign, it is more accurate to say that the sequence was selected from a series than that each substitution was predicted in advance (Raun 1998).
For a researcher, the comparison has a practical use. When reading a paper that used a GHRP-class peptide, check which sequence was used before transferring a conclusion to another one. Potency, duration and selectivity in the papers cited here are properties of the specific molecule tested, and the difference between a hexapeptide and a pentapeptide with different aromatic residues is large enough that results should not be assumed to carry across without a direct comparison.
What the identity and purity checks look for
An HPLC trace shows how much of the signal comes from the main peak, which is how the ≥98% figure on the product page is defined. A mass measurement confirms the main peak has the expected molecular weight. Neither tells the full story alone: HPLC cannot name the peak, and mass does not quantify it. Neither separates a molecule from its all-L or partly-L diastereomer without a reference standard. Where a certificate is published for a lot it appears in the COA library, and how to read a COA and ipamorelin purity testing explain the fields. Understanding HPLC purity explains why the figure is chromatographic.
If a lab needs to prepare a stock, use C = m / (MW × V) with the vial mass and 711.9 g/mol as the molecular weight, and enter the same figures in the reconstitution calculator. Remember that purity and net content are different numbers; peptide content below 100% of the weighed mass will shift the true concentration.
Structure and handling in one view
The product page states storage at 2–8 °C with −20 °C for long-term holding and protection from heat, moisture and light. The structural features above explain why a short peptide with D-residues and Aib tolerates handling reasonably well yet still deserves care: it contains a basic residue and aromatic residues that stick to plastic and glass, and the imidazole of histidine can be sensitive to metal ions and oxidation. Use low-binding tubes, keep solutions cold, and aliquot. Related structural work is on the amino acid sequences guide, and the catalog is on the shop page. All material is for laboratory research use only; not for human or animal consumption.
Frequently asked questions
What is the sequence of ipamorelin?
Aib-His-D-2-Nal-D-Phe-Lys-NH2, a pentapeptide with an N-terminal aminoisobutyric acid, two D-configured aromatic residues and an amidated C-terminus.
What is the molecular formula and mass?
C38H49N9O5, about 711.9 g/mol. A protonated ion in positive-mode mass spectrometry is expected near m/z 712.4.
What is Aib and why is it in the sequence?
Aib is alpha-aminoisobutyric acid, a non-proteinogenic residue with two methyl groups on the alpha carbon. It restricts backbone rotation and is used to protect an end of a peptide from enzymatic cleavage.
Why does ipamorelin contain D-amino acids?
D-2-naphthylalanine and D-phenylalanine resist enzymes that cleave L-amino-acid chains and shape how the aromatic side chains are presented to a receptor.
How was ipamorelin discovered?
According to the original report, it was identified in a series of compounds lacking the central Ala-Trp dipeptide of GHRP-1 during a chemistry program, after earlier work on GHRP-6 and enkephalin-based designs.
How is ipamorelin synthesized?
By solid-phase peptide synthesis on a resin that yields a C-terminal amide, followed by acid cleavage, reversed-phase HPLC purification and freeze-drying.
Which steps are hardest to carry out?
Coupling hindered residues such as Aib and 2-naphthylalanine, and limiting epimerization, because incomplete coupling and diastereomers are the main by-products.
Does an HPLC purity of 98% prove the identity?
No. It describes the chromatographic profile. Identity needs a mass measurement or other confirmation, and net peptide content is a separate quantity.
How should ipamorelin be stored?
The product page states refrigeration at 2-8 C, -20 C for long-term storage, and protection from heat, moisture and light.
Where can a certificate be found?
In the COA library, where one has been published for a lot.
Related reading: Ipamorelin and CJC-1295: Receptor Synergy Research, Ipamorelin History: From GHRPs to the Ghrelin Receptor, Ipamorelin Mechanism: GHS Receptor Signaling Explained.
References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
- Momany FA, et al. Design, synthesis, and biological activity of peptides which release growth hormone in vitro. Endocrinology. 1981;108(1):31-39. doi:10.1210/endo-108-1-31
- Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. doi:10.1210/endo-114-5-1537
- Karle IL, Balaram P. Structural characteristics of alpha-helical peptide molecules containing Aib residues. Biochemistry. 1990;29(29):6747-6756. doi:10.1021/bi00481a001
- Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. doi:10.1021/ja00897a025
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974
